Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4SE5)

Drug Name
Pyrrolo-pyrrolone derivative 1 Drug Info
Synonyms PMID26924192-Compound-34
Cross-matching ID
PubChem CID
122553486
TTD Drug ID
DMN4SE5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bromodomain-containing protein 4 (BRD4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPI-0610 DMPXOYJ Myelofibrosis 2A20.2 Phase 3 [2]
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [2]
PLX2853 DMX168L Acute myeloid leukaemia 2A60 Phase 1/2 [3]
RVX-208 DM1LO8K Alzheimer disease 8A20 Phase 1/2 [2]
INCB57643 DMBGU7V Advanced malignancy 2A00-2F9Z Phase 1/2 [3]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [3]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [4]
GSK525762 DMPAWBN Haematological malignancy 2B33.Y Phase 1 [2]
TEN010 DM4UOY5 Advanced solid tumour 2A00-2F9Z Phase 1 [2]
AZD5153 DMW4GM2 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Bromodomain-containing protein 3 (BRD3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [3]
PMID26924192-Compound-104 DM346EU N. A. N. A. Patented [1]
PMID26924192-Compound-102 DMEJ107 N. A. N. A. Patented [1]
PMID26924192-Compound-103 DMWOCP7 N. A. N. A. Patented [1]
PMID26924192-Compound-105 DMAWLGI N. A. N. A. Patented [1]
XD14 DMUMACD Discovery agent N.A. Investigative [5]
GW841819X DMRL9IN Discovery agent N.A. Investigative [6]
PMID24000170C36 DMHUWZS Discovery agent N.A. Investigative [7]
PMID24000170C38 DMOLRIY Discovery agent N.A. Investigative [7]
I-BET151 DMYRUH2 Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Bromodomain-containing protein 2 (BRD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [2]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [3]
PMID26924192-Compound-104 DM346EU N. A. N. A. Patented [1]
PMID26924192-Compound-102 DMEJ107 N. A. N. A. Patented [1]
PMID26924192-Compound-103 DMWOCP7 N. A. N. A. Patented [1]
PMID26924192-Compound-105 DMAWLGI N. A. N. A. Patented [1]
PMID26924192-Compound-106 DM9HRZJ N. A. N. A. Patented [1]
XD14 DMUMACD Discovery agent N.A. Investigative [5]
GW841819X DMRL9IN Discovery agent N.A. Investigative [6]
PMID24000170C36 DMHUWZS Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bromodomain-containing protein 2 (BRD2) TTDP48B BRD2_HUMAN Inhibitor [1]
Bromodomain-containing protein 3 (BRD3) TTHE657 BRD3_HUMAN Inhibitor [1]
Bromodomain-containing protein 4 (BRD4) TTRA6BO BRD4_HUMAN Inhibitor [1]

References

1 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
2 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
5 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9.
6 Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
7 Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9.
8 Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33.